Important Short Interest Filing: What’s in SKYSTAR BIO PHARAMACEUTICAL COMPANY (OTCMKTS:SKBI) After Rise in Shorted Shares?

November 16, 2016 - By Vivian Park   ·   0 Comments

Important Short Interest Filing: What’s in SKYSTAR BIO PHARAMACEUTICAL COMPANY (OTCMKTS:SKBI) After Rise in Shorted Shares?

The stock of SKYSTAR BIO PHARAMACEUTICAL COMPANY (OTCMKTS:SKBI) registered an increase of 1150% in short interest. SKBI’s total short interest was 10,000 shares in November as published by FINRA. Its up 1150% from 800 shares, reported previously. With 9,300 shares average volume, it will take short sellers 1 days to cover their SKBI’s short positions. The stock 0.02% or $0 on November 15, hitting $0.215. It is up 21.43% since April 14, 2016 and is downtrending. It has underperformed by 26.12% the S&P500.

Skystar Bio-Pharmaceutical Co., Ltd

SKBI Company Profile

Skystar Bio-Pharmaceutical Co., Ltd., incorporated on September 24, 1998, is a maker and distributor of veterinary medicines and healthcare products in China. The Firm develops, makes, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine (TCM); topicals, supplements, probiotics, and diagnostic kits and animal, animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets within China. The Firm operates four product lines: Probiotics, Veterinary Medicine, Veterinary Vaccines and Feed Additives.

More notable recent Skystar Bio-Pharmaceutical Company (OTCMKTS:SKBI) news were published by: Marketwired.com which released: “Skystar Bio-Pharmaceutical Announces Final Delisting From Nasdaq and Continued …” on February 26, 2016, also Marketwired.com with their article: “Skystar Bio-Pharmaceutical to File Financial Results for First Quarter of …” published on May 15, 2014, Streetinsider.com published: “Kandi Technologies Group (KNDI) Announces Two Key Executive Appointments” on November 14, 2016. More interesting news about Skystar Bio-Pharmaceutical Company (OTCMKTS:SKBI) were released by: Seekingalpha.com and their article: “The Perils Of Value Microcap Research And The Example Of Akers Biosciences” published on November 04, 2014 as well as Seekingalpha.com‘s news article titled: “Price-To-Book Values: Use Caution” with publication date: January 31, 2014.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Vivian Park


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>